AU2017348826B2 - Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor - Google Patents

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor Download PDF

Info

Publication number
AU2017348826B2
AU2017348826B2 AU2017348826A AU2017348826A AU2017348826B2 AU 2017348826 B2 AU2017348826 B2 AU 2017348826B2 AU 2017348826 A AU2017348826 A AU 2017348826A AU 2017348826 A AU2017348826 A AU 2017348826A AU 2017348826 B2 AU2017348826 B2 AU 2017348826B2
Authority
AU
Australia
Prior art keywords
group
optionally substituted
phenyl
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017348826A
Other languages
English (en)
Other versions
AU2017348826A1 (en
Inventor
Liguang DAI
Xiaowei DUAN
Meng Guo
Yongxin Han
Yuandong Hu
Fansheng KONG
Hong Luo
Yong Peng
Yinghui Sun
Shanchun WANG
Wei Wu
Hongjiang Xu
Ling Yang
Yanqing Yang
Zhaobai ZHONG
Li Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of AU2017348826A1 publication Critical patent/AU2017348826A1/en
Application granted granted Critical
Publication of AU2017348826B2 publication Critical patent/AU2017348826B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017348826A 2016-10-28 2017-10-27 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor Active AU2017348826B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610970314.3 2016-10-28
CN201610970314 2016-10-28
CN201710044000 2017-01-21
CN201710044000.5 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (2)

Publication Number Publication Date
AU2017348826A1 AU2017348826A1 (en) 2019-05-23
AU2017348826B2 true AU2017348826B2 (en) 2021-12-02

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017348826A Active AU2017348826B2 (en) 2016-10-28 2017-10-27 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Country Status (15)

Country Link
US (1) US10829492B2 (enExample)
EP (1) EP3533796B1 (enExample)
JP (1) JP7046940B2 (enExample)
KR (1) KR102616249B1 (enExample)
CN (1) CN109890820B (enExample)
AU (1) AU2017348826B2 (enExample)
CA (1) CA3041942C (enExample)
DK (1) DK3533796T3 (enExample)
ES (1) ES2896943T3 (enExample)
HU (1) HUE057733T2 (enExample)
MX (1) MX380283B (enExample)
PL (1) PL3533796T3 (enExample)
PT (1) PT3533796T (enExample)
RU (1) RU2764523C2 (enExample)
WO (1) WO2018077246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
TW202033526A (zh) * 2018-12-07 2020-09-16 大陸商貝達藥業股份有限公司 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途
WO2020187291A1 (zh) 2019-03-19 2020-09-24 华中师范大学 吡唑并嘧啶化合物和药物组合物及其应用
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021249450A1 (zh) * 2020-06-11 2021-12-16 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN113200963A (zh) * 2021-03-31 2021-08-03 广东石油化工学院 N-(吡咯基)-3-吡唑基胺及其制备方法
EP4335441B1 (en) * 2021-05-03 2025-05-28 JBKLAB Co., Ltd. Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2014143242A1 (en) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) * 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
CN104650092B (zh) 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
HUE046727T2 (hu) * 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2014143242A1 (en) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Also Published As

Publication number Publication date
PL3533796T3 (pl) 2022-01-17
ES2896943T3 (es) 2022-02-28
DK3533796T3 (da) 2021-11-08
MX2019004847A (es) 2019-08-29
AU2017348826A1 (en) 2019-05-23
MX380283B (es) 2025-03-12
RU2019114600A3 (enExample) 2021-02-20
JP7046940B2 (ja) 2022-04-04
CN109890820A (zh) 2019-06-14
CA3041942C (en) 2023-03-14
RU2764523C2 (ru) 2022-01-18
US20190352306A1 (en) 2019-11-21
KR102616249B1 (ko) 2023-12-21
BR112019008656A8 (pt) 2022-06-07
JP2019537588A (ja) 2019-12-26
HUE057733T2 (hu) 2022-06-28
CN109890820B (zh) 2020-11-03
PT3533796T (pt) 2021-11-18
RU2019114600A (ru) 2020-11-30
CA3041942A1 (en) 2018-05-03
EP3533796A4 (en) 2020-06-03
EP3533796B1 (en) 2021-09-29
US10829492B2 (en) 2020-11-10
BR112019008656A2 (pt) 2019-07-09
WO2018077246A1 (zh) 2018-05-03
KR20190067913A (ko) 2019-06-17
EP3533796A1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
CA3041942C (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
AU2014324595B2 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
AU2018320021B2 (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
AU2009249186B2 (en) Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
CA2778291C (en) Akt inhibitors
AU2019382504B2 (en) Cyclic ureas
CA3121408A1 (en) Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
TWI790227B (zh) 布魯頓氏酪胺酸激酶之抑制劑
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
CA3152690A1 (en) Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
CA3234429A1 (en) Ras inhibitors, compositions and methods of use thereof
JP2023515095A (ja) 置換アリール系化合物
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico
KR20250148666A (ko) Sgk1의 억제제로서의 아미노-치환된 피롤로트리아진 유도체
CA3172186A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40002935B (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40002935A (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)